Bronstein, Gewirtz & Grossman, LLC and Kuehn Law, PLLC launched investigations into Medpace Holdings on August 10, 2026. The probes examine whether the company and its executives misrepresented business conditions and backlog cancellation rates.
Lawsuits allege Medpace issued overly optimistic growth projections to investors. The company specifically claimed it could maintain a 1.15 book-to-bill ratio.
These projections allegedly led to artificially inflated stock prices. The law firms seek investors who purchased securities prior to April 22, 2025, to determine if fiduciary duties were breached.